Clinical trials: SCHIZOPHRENIA 1 (Disorder)
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks.
- Trial name
- NCT07423546
- Testing
- Xanomeline and trospium chloride (KarXT)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Tobacco Use Cessation, Tobacco Use Disorder
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a…
- Conditions
- Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia
- Trial name
- NCT00124683
- Testing
- Bupropion, nicotine transdermal patch
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
SCHIZOPHRENIA 1 (Disorder), Hospitalized Adult Patients
Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia
The current study aims to examine the feasibility, acceptability, and preliminary effectiveness of a Hatha yoga-based group intervention on reminiscence functions and mindfulness in a sample of patients hospitalized for…
- Trial name
- NCT07454200
- Testing
- Intervention Arm: Hatha Yoga
- Volunteers
- 36 people
- Sponsor
- The Hashemite University
SCHIZOPHRENIA 1 (Disorder), Substance Abuse
Comparison of the Italian and U.S. Forensic Models for Dual-diagnosis Offenders: a 3-year Longitudinal Study
This study aims to compare the Italian and U.S. forensic models in the treatment of offenders with dual diagnosis through a three-year longitudinal design.
- Trial name
- NCT07585656
- Volunteers
- 600 people
- Sponsor
- University of Bari
Cognitive Function 1, Social
Social Cognition Assessment in Young Adults
The primary objective of this study is to determine the efficacy and feasibility of a battery of neuropsychological measures evaluating social cognition and behavior in young adults diagnosed with schizophrenia, autism spectrum…
- Trial name
- NCT02922400
- Testing
- Social Cognition Assessment and Training
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Dallas
Healthy
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects.
- Trial name
- NCT01530529
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who…
- Trial name
- NCT01515423
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 174 sites in United States, Argentina and 24 more
- Volunteers
- 1,429 people
- Sponsor
- Janssen Research & Development, LLC
SCHIZOPHRENIA 1 (Disorder), Sensory Perceptual Characteristics
Precision HD-tACS for Enhancing Sensory Experience in Schizophrenia
To ensure unified sensory perception, the brain must link information from different senses across time and space. This unification of perception often referred to as a perceptual "binding constraint" is a prerequisite for any…
- Trial name
- TherACles (NCT07632261)
- Testing
- Transcranial neurostimulation
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Schizophrenic Disorder
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia.
- Trial name
- NCT00206115
- Testing
- Seroquel Sustained Release (SR), Seroquel Immediate Release (IR)
- Where
- 31 sites in Bulgaria, Greece and 6 more
- Volunteers
- 535 people
- Sponsor
- AstraZeneca
SCHIZOPHRENIA 1 (Disorder), Alcohol Use Disorder
Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia
The purpose of the study: obtaining knowledge about the impact of Snoezelen® therapy on the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Alcohol Use Disorder, Alcohol Dependence (Primary Condition)
- Trial name
- NCT07748078
- Testing
- Snoezelen® therapy for 6 weeks, Snoezelen® therapy for 12 weeks
- Where
- 2 sites in Poland
- Volunteers
- 140 people
- Sponsor
- The Jerzy Kukuczka Academy of Physical Education in Katowice
Schizophrenia
Digoxin Drug-Drug Interaction With Lurasidone HCl
The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.
- Trial name
- NCT01082289
- Testing
- Lurasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Early Course Schizophrenia Spectrum Disorder
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia.
- Trial name
- NCT04457310
- Testing
- CVL-562 (PF-06412562) 1 mg, CVL-562 (PF-06412562) 4 mg, CVL-562 (PF-06412562) 15 mg
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Yale University
Schizophrenia
One Year Drug Treatment in First-Episode Schizophrenia
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
- Trial name
- NCT00159081
- Testing
- Haloperidol, Risperidone (drug)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Tobacco Use Disorder
Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1
The purpose of this study is to test the use of High-Dose versus Regular-Dose Nicotine Patch for Nicotine Dependence in Individuals with Schizophrenia or Schizoaffective Disorder
- Trial name
- NCT00046813
- Testing
- Nicotine patch
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Agitation,Psychomotor
Outcomes of Antipsychotic Medication Used in the Emergency Department
To review records of patients treated with antipsychotics (including Adasuve, Geodon, Haldol) in order to evaluate outcomes.
- Trial name
- OAMED (NCT02504450)
- Testing
- Adasuve, Alternative medications
- Volunteers
- 93 people
- Sponsor
- Wake Forest University Health Sciences
Healthy
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of PF-03463275 oral controlled release formulation in…
- Trial name
- NCT01159626
- Testing
- PF-03463275
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia, Psychoses
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment.
- Trial name
- NCT00159133
- Testing
- antipsychotics vs. Lorazepam (Drugs)
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia
Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios
Schizophrenia is a chronic and devastating major psychiatric disorder. Family, twin, and adoption studies indicated that schizophrenia has a significant genetic component.
- Trial name
- NCT00155506
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Psychotic Disorder, Cognitive Function 1, Social
Social Cognition and Interaction Training for Adults With Psychotic Disorders: An Open Pilot Study in Finland
33 individuals with a psychotic disorder were given 22-24 sessions weekly or twice weekly of Social Cognition and Interaction Training (SCIT) and evaluated at the baseline and after the intervention.
- Trial name
- NCT02399020
- Testing
- Social Cognition and Interaction Training
- Where
- Finland
- Volunteers
- 33 people
- Sponsor
- Helsinki University Central Hospital